
Repotrectinib is a tyrosine kinase inhibitor (TKI) that targets ROS1 and is administered as an oral therapy for treatment of locally advanced or metastatic ROS1-positive non–small cell lung cancer.

Repotrectinib is a tyrosine kinase inhibitor (TKI) that targets ROS1 and is administered as an oral therapy for treatment of locally advanced or metastatic ROS1-positive non–small cell lung cancer.

The study also found that 82% of the surveyed physicians reported not getting labs to help determine treatment options for their patients.

A single infusion of VERVE-101, a gene editing tool, improved both blood PCSK9 protein levels and blood LDL-C levels in 10 individuals with high-risk HeFH.

The RESCUE BT2 trial sheds further light on the agent’s potential.

The products include Crovalimab, Dapagliflozin, Secukinumab, Roflumilast

This interstate agreement can empower pharmacists to respond to large-scale emergencies

Expert discusses changes health care professionals should know about drug coverage and out-of-pocket costs through the IRA

The approval marks the sixth cancer type PD-L1 IHC 22C3 pharmDx has been granted, and the first for GEJ

Taurolidine and heparin (Defencath; CorMedix) is indicated to reduce catheter-related bloodstream infections for adults with kidney failure who are receiving chronic hemodialysis via central venous catheter

The approval will benefit patients who have difficulty swallowing, dysphagia, or high taste sensitivities and struggle to adhere to the original antibiotic.

The genes that predispose a person to sleep problems can impact that person across their entire lifetime, so interventions targeted toward a younger audience could be beneficial.

Researchers provided recommendations based on the current status of COVID-19 infection and role of therapies.

The business model took time to catch up to pharmacy’s potential, and community-based patient care leads the way

Acne is one of the most common conditions, with about 50 million Americans dealing with acne annually.

Session speaker Powell-Wiley explains how screening for SDOH in patients as cardiovascular-kidney-metabolic syndrome stages progress can help better understand their individual social needs.

The products include Reserve Sleep Gummies, Menopause Stage Indicator, Organic Ashwagandha Gummies, and Precise Pain Relieving Cream.

The drug may be a risk factor for dementia-related illnesses.

In this episode, you'll hear a conversation with Ron Lanton, partner at Lanton Law, who gets us up to speed on all of the legal cases surrounding this issue thus far.

According to the authors, these results contribute to developing information that associate lymphedema with localized changes in immunity and a susceptibility for cancer.

Compared to the standard prenatal vitamin alone, vitamin D supplementation with the prenatal vitamin reduced the risk of asthma and wheezing in children by approximately 50%.

Ince describes why patients who are considered fragile are often underdiagnosed and undertreated, and that the VOYAGER PAD analyses can encourage the treatment of the fragile population.

Even with the current available treatment options, it is important to recognize the importance of masking, particularly for those with immunocompromised conditions.

Lessons from the pharmacy taught her about good communication. Now it’s her turn to educate pharmacists.

The AZALEA-TIMI 71 randomized trial evaluated the safety and tolerability of 2 blinded doses of the novel factor XI inhibitor abelacimab compared with open-label rivaroxaban.

Homemade indoor air filters can trap and remove 99% of airborne viruses.

The presence of the TPSAB1 gene could help clinicians identify increased food allergies.

Safe handling of hazardous drugs plays a vital role in patient care.

Counseling is particularly important for pediatric patients or those with other medical conditions

Bonaca also notes that pharmacists can play a key role in educating patients and clinicians about the appropriate use and dosing of antithrombotic drugs for vascular protection.

Harrington discusses how the performance of milvexian in prior phase 2 trials focused on different patient populations creates the foundation for future research.